The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation

Anita Chawla (), Ginger Carls, Edmund Deng and Edward Tuttle

PharmacoEconomics, 2015, vol. 33, issue 7, 749-763

Abstract: Regulatory policy and litigation risk both played a role in anti-obesity drug development; however, product revenue—reflecting efficacy at acceptable levels of safety—was by far the most important factor. To date, relatively modest sales associated with recent product introductions suggest that developing a product that is sufficiently efficacious with an acceptable level of safety continues to be the primary challenge in this market. Copyright Springer International Publishing Switzerland 2015

Date: 2015
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.1007/s40273-015-0300-0 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:33:y:2015:i:7:p:749-763

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-015-0300-0

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().